Download

Download Full Text (596 KB)

Description

Background:

Depression affects millions globally - Treatment-resistant depression (TRD) is defined as failure to respond to two antidepressant trials of adequate dose and duration

Traditional Treatment for TRD:

Switching or adding medications atypical antipsychotics - Limitations include delayed action, side effects, and limited efficacy

Alternative Treatment Options:

- Ketamine:

  • A dissociative anesthetic with potential antidepressant effects
  • Targets the NMDA receptor and activates AMPA receptor.
  • Shows rapid and potent antidepressant effects; however, not FDA-approved for depression

- Monoamine Oxidase Inhibitors (MAOIs):

  • Antidepressants used since the 1950s
  • Inhibits the enzyme metabolizing neurotransmitters.
  • Limitations: Dietary restrictions and drug interactions and longstanding safety concerns

Importance of Comparison:

Given limitations of traditional treatments and promising results from Ketamine and MAOIs, there's a need to compare their safety and efficacy. This will provide clinicians with informed choices for their patients.

Objective:

To compare the safety and efficacy of ketamine and MAOIs for TRD to guide clinical decisions and future research.

Publication Date

8-17-2023

Keywords

MAOIs, ketamine, TRD

Disciplines

Medicine and Health Sciences | Psychiatric and Mental Health

Comments

Capstone presentations were completed in partial fulfillment of the Master of Science degree in Physician Assistant Studies at Thomas Jefferson University.

Document Type

Poster

Safety and Efficacy of Adjunctive Esketamine vs. MAOIs in TRD in Adults

Share

COinS